Heartworm disease causes severe cardiopulmonary damage in dogs, yet it is entirely preventable with monthly or annual preventative medication — making untreated cases a welfare failure driven by owner access and awareness gaps.
Heartworm disease welfare involves a prolonged course of subclinical damage followed by progressive, distressing cardiopulmonary disease. Dogs with heartworm-induced pulmonary hypertension experience breathlessness, exercise intolerance, and syncope (fainting) — experiences that cause fear and significantly impair quality of life. The treatment process itself carries welfare costs: melarsomine injections cause local tissue reactions, and the mandatory exercise restriction during the 6-8 week treatment period (to prevent pulmonary embolism from dying worms) causes psychological frustration in active dogs. Prevention is unambiguously the welfare-preferred approach: monthly preventatives given consistently eliminate disease risk before any welfare cost accrues. Barriers to prevention include cost, veterinary access in endemic rural areas, and owner unawareness of geographic risk. Low-cost heartworm prevention programmes in endemic regions represent important welfare infrastructure, particularly for owned but unvaccinated working dogs.